April 7, 2022 4:43pm

What justifies the share pricing, it’s NOT investor advocacy?  The short-term and near-term pricing “shades” the long-term price targets

Pre-open indications: 2 HITS, 4 MISS and 1 Pimp/Pump and Promote - usual suspect Biostage (BSTG -$0.63)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

 

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +87.99 points (+0.26%); the S&P closed UP +19.06 points (+0.43%) while the Nasdaq closed UP +8.48 points (+0.06%)

 

Henry’omics:

Indexes rose after two (2) negative closes, as investors still fear the Fed’s latest plans to tighten monetary policy and combat rising inflation could further slow the economy.

“Thursday’s moves come after the Fed released minutes from its March meeting on Wednesday, which showed that officials planned to reduce their trillions in bond holdings with a consensus amount around $95 billion. Meanwhile, policymakers indicated that one or more 50 basis-point interest rate hikes could be warranted to battle surging inflation.” <CNBC>

Concern about interest rates continued to be high on the minds of investors this week after several Fed officials came out strongly in favor of hiking rates and reducing the Fed's balance sheet. <IBD>

Economic Data Docket: Jobless claims totaled 166,000 last week, the lowest in more than five decades

·         The decline in unemployment claims came as a surprise to economists, well below the Dow's previous projection of 200,000

·         The number - the lowest since November 1968 - suggests employers are now retaining workers in an increasingly tight labor market

·         Weekly unemployment claims have been falling for most of the year since reaching a previously unseen high of 6.15 million in March 2020 - more than 36 times last week's number - during the height of the pandemic.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened negative at 15 up/18 downs, 2 flats, stayed negative at the mid-day at 5/28 and 2 flats, ending with a negative close of 7/26 and 2 flats;

 

52-weekor all-time lows:

  • AVROBIO (AVRO) at $1.24
  • Caribou Biosciences (CRBU) at $8.27
  • Homology Medicine (FIXX) at $2.50

 

Pre-open Indications: 2 HIT: SELL: Global Blood Therapeutics (GBT -$0.82); BUY: AxoGen (AXGN $0.00), > 4 MISS: BUY: Beam Therapeutics (BEAM -$1.43), CRISPR Therapeutics (CRSP -$2.18), Editas Medicine (EDIT -$0.67), Regenxbio (RGNX -$0.76)> 1 Pimp/Pump/Promote: <Biostage (BSTG) closed flat (-$0.63) with 430 shares traded after Wednesday’s  -$0.05 with 1,527 shares traded, Tuesday’s +$0.59 with 8,743 shares traded, Monday’s +$0.49 with 8,809 shares traded, Friday’s $0.00 with 10 shares traded and last Thursday’s -$0.10 with 124 shares traded>     

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added with 35 to date <some dropped and others added>

 

Key Metrics:

  • Thursday - Sector volume was LOW with 2 of the 2-upside having higher than the 3-month average volume with LOW volume of 2 of 2-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +1.08% and the XBI was down -1.06%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.55 points or -2.49% at 21.55

 

Jumping with share pricing momentum (7 of 7):

  • Alnylam Pharmaceuticals (ALNY +$3.78 after Wednesday’s-$1.44, Tuesday’s -$1.86 after Monday’s -$7.52),
  • Ionis Pharmaceuticals (IONS +$0.58),
  • Voyager Therapeutics (VYGR +$0.15),
  • Solid Biosciences (SLDB +$0.10),
  • Cellectis SA (CLLS +$0.08),
  • Brainstorm Cell Therapeutics (BCLI +$0.06),
  • Verastem (VSTM +$0.03),

Hammered in today’s market (10 of 26):

  • CRISPR Therapeutics (CRSP -$2.18 after Wednesday’s -$1.36, Tuesday’s -$2.03 and Monday’s +$3.36),
  • Intellia Therapeutics (NTLA -$1.59 after Wednesday’s -$2.61 after Tuesday’s -$6.05),
  • Sage Therapeutics (SAGE -$1.53),
  • Beam Therapeutics (BEAM -$1.43 after Wednesday’s -$1.65, Tuesday’s -$5.90 and Monday’s +$2.41),
  • Fate Therapeutics (FATE -$1.16 after Wednesday’s +$0.65, Tuesday’s -$2.31 and Monday’s +$1.07),
  • Vericel (VCEL -$0.95),
  • Global Blood Therapeutics (GBT -$0.82 after Wednesday’s -$0.52, Tuesday’s +$0.09 and Monday’s +$1.39),
  • Regenxbio (RGNX -$0.76 after Wednesday’s -$0.59 and Tuesday’s -$0.67),
  • Ultragenyx (RARE -$0.69 after Wednesday’s +$2.15, Tuesday’s +$2.55 and Monday’s +$0.78),
  • Editas Medicine (EDIT -$0.67 after Wednesday’s -$0.58, Tuesday’s -$1.02 and Monday’s +$1.13),

Flat:

  • AxoGen (AXGN)

 

April, Q2/2022:

  • Thursday closed negative with 7 incliners, 26 decliners and 2 flats

 

The BOTTOM LINE:  Even I expected the oversold to at the least gain some altitude.

Volume also was barely there … as many companies prepare for a Q1/22 response to earnings – and it might be ugly.

I expect volatility as the electronic trading manages any upside opportunity.

Investors are more than worried about pricey valuations that (in my mind’s eye) have NO basis.

As I had stated, “On what (?) does this sector stay up as it can be a fickle place, as we’ve seen this year. Oversold/ Overbought – they bunch and then alternate … how lone are we going to experience this selling opportunity?

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.